U.S. Food and Drug Administration (FDA) approved a new delivery device for Neulasta (pegfilgrastim) for non-Hodgkin patients who do not need to return to the clinic the day after chemotherapy. More >
Welcome to Focus on PTCL
The FocusOnPTCL.org website is designed to provide helpful information and resources to patients, caregivers, physicians, and others affected by peripheral T-cell lymphoma (PTCL).
We invite you to browse the site to learn more about PTCL.
Getting the Facts
Peripheral T-cell lymphoma (PTCL) comprises a group of rare and usually aggressive non-Hodgkin lymphomas (NHL) that develop from mature T-cells. Peripheral T-cell lymphoma represents a spectrum of T-cell lymphomas and accounts for approximately 10 percent to 15 percent of all NHL cases in the United States.
Recent research into peripheral T-cell lymphoma has led to significant advancements in the understanding and classification of the disease and its subtypes. Research continues on multiple fronts to develop better treatments for PTCL. We hope you will find the information presented here useful in understanding your disease and discussing it with your physician.